As Alexion Pharmaceuticals (ALXN) Valuation Declined, Dsm Capital Partners LLC Has Upped Its Position by $34.02 Million

January 17, 2018 - By Jacob Falcon

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.20, from 1.37 in 2017Q2. It dived, as 36 investors sold ALXN shares while 174 reduced holdings. 78 funds opened positions while 167 raised stakes. 206.89 million shares or 0.54% less from 208.01 million shares in 2017Q2 were reported. Guardian Life Of America has invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Loomis Sayles & Lp invested 0.04% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Premier Asset Mngmt Ltd Co holds 1.72% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 54,540 shares. Moreover, Magnetar Lc has 0.01% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Bnp Paribas Arbitrage reported 0.05% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Bp Public Limited Com holds 0.13% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) or 26,000 shares. Webster Savings Bank N A reported 0.2% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Clearbridge Limited Liability owns 3.23 million shares. California Pub Employees Retirement System stated it has 463,579 shares or 0.1% of all its holdings. 271,171 were accumulated by Neuberger Berman Group Inc Limited Liability Corporation. Tokio Marine Asset Management Com invested in 0.33% or 15,786 shares. United Kingdom-based Rathbone Brothers Public Limited Co has invested 0.01% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Tiaa Cref Inv Management Lc invested 0.33% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Verition Fund Management Limited Liability Com has invested 0.04% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Moreover, Evercore Wealth Mgmt Limited Com has 0.01% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 1,709 shares.

Since July 31, 2017, it had 0 insider purchases, and 6 sales for $2.74 million activity. O’Neill Julie sold 11,160 shares worth $1.56 million. $121,751 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Veneman Ann M. Another trade for 120 shares valued at $16,800 was sold by Wagner Heidi L.

Dsm Capital Partners Llc increased its stake in Alexion Pharmaceuticals (ALXN) by 20.82% based on its latest 2017Q3 regulatory filing with the SEC. Dsm Capital Partners Llc bought 243,001 shares as the company’s stock declined 11.63% while stock markets rallied. The hedge fund held 1.41M shares of the health care company at the end of 2017Q3, valued at $197.83 million, up from 1.17 million at the end of the previous reported quarter. Dsm Capital Partners Llc who had been investing in Alexion Pharmaceuticals for a number of months, seems to be bullish on the $27.31 billion market cap company. The stock decreased 1.79% or $2.23 during the last trading session, reaching $122.25. About 1.48M shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since January 17, 2017 and is downtrending. It has underperformed by 34.82% the S&P500.

Dsm Capital Partners Llc, which manages about $5.78B and $7.05B US Long portfolio, decreased its stake in Charles Schwab (NYSE:SCHW) by 353,690 shares to 4.91 million shares, valued at $214.55M in 2017Q3, according to the filing. It also reduced its holding in Regeneron Pharmaceuticals (NASDAQ:REGN) by 21,642 shares in the quarter, leaving it with 1.06M shares, and cut its stake in Ctrip.Com International (NASDAQ:CTRP).

More important recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: which released: “Alexion Pharmaceuticals: A High Conviction, Large Cap Orphan Disease Pick For 2018” on January 08, 2018, also published article titled: “First Week of August 2018 Options Trading For Alexion Pharmaceuticals (ALXN)”, published: “JPMorgan Healthcare Conference next week” on January 04, 2018. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was released by: and their article: “Oppenheimer Stays Bullish On Alexion Pharma” with publication date: December 20, 2017.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 28 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Alexion Pharmaceuticals Inc. had 89 analyst reports since July 27, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, July 21 by BMO Capital Markets. The rating was maintained by Robert W. Baird with “Hold” on Tuesday, September 12. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Buy” rating given on Tuesday, September 20 by Citigroup. On Tuesday, November 29 the stock rating was upgraded by Barclays Capital to “Overweight”. As per Monday, July 11, the company rating was upgraded by Credit Suisse. The firm has “Buy” rating given on Monday, October 23 by Stifel Nicolaus. The firm has “Underperform” rating by FBR Capital given on Thursday, September 15. As per Monday, July 27, the company rating was initiated by JP Morgan. Stifel Nicolaus maintained the shares of ALXN in report on Friday, October 27 with “Buy” rating. As per Thursday, February 4, the company rating was maintained by UBS.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.